158 related articles for article (PubMed ID: 36794128)
1. High expression of FGFR3 predicts a better prognosis for patients with non-small cell lung cancer in a Chinese population.
Lin YE; Long HD; Chen CC; Liu GC; Li F; Tian YH; Dai L
J Thorac Dis; 2023 Jan; 15(1):101-111. PubMed ID: 36794128
[TBL] [Abstract][Full Text] [Related]
2. FGFR1, 2 and 3 protein overexpression and molecular aberrations of FGFR3 in early stage non-small cell lung cancer.
Theelen WS; Mittempergher L; Willems SM; Bosma AJ; Peters DD; van der Noort V; Japenga EJ; Peeters T; Koole K; Šuštić T; Blaauwgeers JL; van Noesel CJ; Bernards R; van den Heuvel MM
J Pathol Clin Res; 2016 Oct; 2(4):223-233. PubMed ID: 27785367
[TBL] [Abstract][Full Text] [Related]
3. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
Xu L; Guo R
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous resistance mechanisms in an EGFR exon 19-mutated non-small cell lung cancer patient treated with erlotinib: Persistent FGFR3-mutation, localized transformation to EGFR-mutated SCLC, and acquired T790M EGFR-mutation.
Santoni-Rugiu E; Grauslund M; Melchior LC; Costa JC; Sørensen JB; Urbanska EM
Lung Cancer; 2017 Nov; 113():14-17. PubMed ID: 29110841
[TBL] [Abstract][Full Text] [Related]
5. Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Wang X; Cao L; Li S; Wang F; Huang D; Jiang R
J Cancer; 2019; 10(26):6703-6710. PubMed ID: 31777599
[No Abstract] [Full Text] [Related]
6. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
7. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers.
Li Z; Zhang Y; Jin T; Men J; Lin Z; Qi P; Piao Y; Yan G
BMC Cancer; 2015 Mar; 15():207. PubMed ID: 25880877
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
9. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
[TBL] [Abstract][Full Text] [Related]
11. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
12. Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer.
Bertz S; Abeé C; Schwarz-Furlan S; Alfer J; Hofstädter F; Stoehr R; Hartmann A; Gaumann AK
Virchows Arch; 2014 Dec; 465(6):687-95. PubMed ID: 25326864
[TBL] [Abstract][Full Text] [Related]
13. Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma.
Nannapaneni S; Griffith CC; Magliocca KR; Chen W; Lyu X; Chen Z; Wang D; Wang X; Shin DM; Chen ZG; Saba NF
PLoS One; 2021; 16(2):e0247498. PubMed ID: 33626078
[TBL] [Abstract][Full Text] [Related]
14. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
Song Z; Wang X; Zheng Y; Su H; Zhang Y
Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
[TBL] [Abstract][Full Text] [Related]
18. Detection of epidermal growth factor receptor (
Guo K; Shao C; Han L; Liu H; Ma Z; Yang Y; Feng Y; Pan M; Santarpia M; Carmo-Fonseca M; Silveira C; Lee KY; Han J; Li X; Yan X
Transl Lung Cancer Res; 2021 Jul; 10(7):3213-3225. PubMed ID: 34430359
[TBL] [Abstract][Full Text] [Related]
19. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
20. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
